Eton Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary

Eton Pharmaceuticals

08/08/2025 04:29

Eton Pharmaceuticals Inc ETON.OQ reported a quarterly adjusted loss of 10 cents​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of -12 cents.  The mean expectation of three analysts for the quarter was for a loss of 4 cents per share. Wall Street expected results to range from -10 cents tozero cents per share.

Revenue rose 108.6% to $18.93 million from a year ago; analysts expected $16.71 million.

Eton Pharmaceuticals Inc's reported EPS for the quarter was a loss of 10 cents​.

The company reported a quarterly loss of $2.59 million.

Eton Pharmaceuticals Inc shares had risen by 7.1% this quarter and gained 14.6% so far this year.

FORECAST CHANGES

The mean earnings estimate of analysts had fallen by about 375.1% in the last three months.​

In the last 30 days, there have been no negative revisions of earnings estimates

RECOMMENDATIONS

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy"

Wall Street's median 12-month price target for Eton Pharmaceuticals Inc is $28.00, about 45.5% above its last closing price of $15.26

This summary was machine generated from LSEG data August 8 at 03:28 a.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Jun. 30 2025
-0.04
0.07
Beat
Mar. 31 2025
0.05
0.07
Beat
Dec. 31 2024
0.00
-0.02
Missed
Jun. 30 2024
-0.01
0.03
Beat